Life sciences
Experts in healthcare access
The access challenges facing healthcare products are becoming more and more complex. With direct experience serving stakeholders across the U.S. healthcare system, we can help you understand the market, identify actionable insights, develop market-ready strategies, and execute to the top of your potential.
Our solutions are tailored to your needs, whether you’re focused on small molecule pharma, gene and cell therapies, rare disease, biosimilars, or medical devices.
Hear from
Milliman Life Sciences leaders
Watch our experts in conversation on key topics affecting the industry.
GLP-1 medications
With benefits far beyond weight loss, patient uptake of GLP-1s is rising. Milliman is analyzing the impact across the healthcare ecosystem to help payers, life sciences companies, and other stakeholders adapt.
Read our latest thought leadership
Direct-to-patient prescription drugs: A framework to help pharmaceutical manufacturers evaluate their strategy
We outline considerations on evaluating medication suitability for manufacturers looking to expand their presence in the direct-to-patient market.
CMMI’s ACCESS model: What health tech providers, life sciences organizations, and ACOs need to know
We detail key information for stakeholders on the Center for Medicare and Medicaid Innovation’s new payment framework.
Increasing diversity in clinical trials
Milliman health researchers discuss strategies and benefits of making sure new medical treatments are tested in patients from a range of backgrounds.
Life sciences by the numbers
Quick takes on key topics affecting pharmaceutical companies and other healthcare stakeholders.
Learn more about our comprehensive suite of services
Milliman Consolidated Health Cost Guidelines™ databases
Claim line detail for medical and prescription drug claims and enrollment.
| Heading | Content | Lines of business | Estimated lives represented | |
|---|---|---|---|---|
| Milliman Proprietary Data | CHSD+ | The Consolidated Health Cost Guidelines Databases (CHSD) includes claim line detail for medical and prescription drug claims and enrollment | Commercial Medicare Advantage Managed Medicaid |
Almost 90 million |
| Milliman Proprietary Data | Medicare PDCD | The Medicare Prescription Drug Consolidated Database includes drug claims and enrollment | Medicare Part D | Over 6 million |
| Industry Data | CMS 100% Research Identifiable Files | Claim line detail for medical and prescription drug claims and enrollment | Fee-for-service (FFS) Medicare Medicare Advantage Medicaid |
All beneficiaries |
| Industry Data | CMS 5% Sample / 100% Data Sets | Claim line detail for medical claims and enrollment | Fee-for-Service (FFS) Medicare | All beneficiaries |
| Industry Data | MarketScan | Claim line detail for medical and prescription drug claims and enrollment | Commercial | 35 million |
| Milliman Proprietary Data | State Discharge | Inpatient discharges, no membership | All | 100% of Admissions in Available States |
Contact us
We’re here to help you break through complex challenges and achieve next-level success.